DNA and RNA Purification Service
Necessity of Purified DNA and RNA
The uses of synthetic DNA and RNA are expanding across various fields, including clinical diagnostics and the development of novel biopharmaceutical therapeutics. DNA and RNA synthesis is a highly efficient process that generates minimal impurities at each step during the synthesis cycle. For example, it is crucial to purify RNAs obtained from enzymatic synthesis or modification reactions before utilization. After in vitro transcription, the RNA needs to be purified to remove unincorporated nucleotides, short aborted transcripts, enzymes, and buffer components. After performing protocols like RNA labeling, DNase I treatment, proteinase K treatment, and mRNA capping, it is crucial to eliminate small molecule and enzyme reaction components. This thorough removal to produce highly purified RNA is necessary for further applications or experiments, such as RNA vaccines.
Fig.1 Types of mRNA vaccines. (Esteban, et al., 2021)
Key Technologies
The key technologies of our DNA and RNA purification service include PAGE-based purification, which separates polynucleotides by size with high resolution, and HPLC-based purification employing three specialized methods: reversed-phase HPLC (separates by hydrophobicity), ion-exchange HPLC (separates by charge), and ion-paired reversed-phase HPLC (enhances resolution for charged molecules), ensuring high-purity outcomes suitable for sensitive downstream applications.
Purified Precision: Where DNA Meets RNA, Perfected by Glyco-Science.
This purified DNA and RNA can be used for diverse downstream applications. As a result, CD BioGlyco offers better methods to purify and analyze these vital biological aptamers to guarantee delivering DNA and RNA of high quality. We have two techniques available to purify and isolate DNA and RNA from synthetic products. These techniques are employed to eliminate reaction by-products and undesired oligonucleotides produced during the synthetic reactions. We primarily utilize PAGE and HPLC for the acquisition of desired compounds derived from synthetic products. We efficiently isolate the desired DNA and RNA and remove any unwanted by-products and impurities that may arise during the synthetic reactions through our techniques.
- PAGE-based DNA and RNA Purification Service
We employ PAGE separation to purify DNA and RNA, which can be performed at either the analytical or preparative scale. PAGE technology separates polynucleotides based on their length, allowing for the differentiation of full-length molecules from truncated ones. Our technique of PAGE separation effectively separates and purifies the desired molecules while eliminating undesired impurities, ensuring a high level of purification for DNA and RNA samples. - HPLC-based DNA and RNA Purification Service
HPLC, a reliable method for analyzing and purifying synthetic DNA and RNA, successfully achieves the separation of polymers with similar sizes and allows for automation.
- Reversed-phase HPLC
Reversed-phase HPLC separates polynucleotides and contaminants by exploiting variations in hydrophobicity. Crude polynucleotides consist of the target product and chemically modified by-products, all exhibiting different levels of hydrophobicity. - Ion-exchange HPLC
Ion-Exchange HPLC is widely employed for the purification and separation of polynucleotides with multiple charges at CD BioGlyco. By utilizing a salt-gradient elution mode on a polymeric adsorbent or porous silica derivatized with tertiary or quaternary ammonium, the ion-exchange HPLC technique enables the effective separation of DNA and RNA. - Ion-paired reversed-phase HPLC
Ion-paired reversed-phase HPLC is an analytical method that enhances resolution by incorporating a low concentration of long-chained alkyl amine into the mobile phase. This alkyl amine interacts with negatively charged oligonucleotides, thereby improving the separation of the analytes.
- Reversed-phase HPLC
Fig.2 The main factors determining the separation properties. (CD BioGlyco)
Workflow
Our streamlined purification workflow is designed for maximum efficiency, transparency, and quality assurance. Each project undergoes a meticulous, multi-stage process to ensure the highest possible nucleic acid yield and integrity.
- Sample Collection and Lysis
The process begins with the careful receipt and preparation of your samples. We employ a combination of physical, chemical, and enzymatic methods to disrupt cell membranes and release nucleic acids into a solution, creating a crude lysate.
- Lysate Clearing
The crude lysate is then processed to remove cellular debris, lipids, and proteins that could interfere with subsequent purification steps. This is a critical stage that ensures the integrity of the downstream purification process.
- Purification
Based on your project requirements, we apply either our PAGE or HPLC purification protocols. For PAGE, we first visualize the DNA or RNA band of interest, carefully excise it from the gel, and then recover the nucleic acid from the gel matrix. For HPLC, the sample is injected into a column where it binds to a resin and is then eluted in a stepwise manner to separate the target molecules.
- Washing and Elution
After purification, the target nucleic acids are washed to remove residual salts, buffers, and other contaminants. The final, highly purified DNA or RNA is then eluted in a low-ionic-strength solution, such as nuclease-free water, to ensure its readiness for your specific downstream application.
- Quality Control and Reporting
Every purified sample undergoes rigorous quality control. We provide comprehensive reports detailing the concentration, purity, and integrity of your nucleic acids, giving you a complete overview of the quality of your sample.
Publication Data
DOI.: 10.3390/ijms17122134
Journal: International Journal of Molecular Sciences
IF: 4.9
Published: 2016
Results: This comprehensive review details advanced methods for purifying and determining the structures of therapeutic oligonucleotides and aptamers. The authors systematically analyze purification techniques—including PAGE, ion-exchange chromatography, and ion-paired reversed-phase HPLC—highlighting their efficacy in isolating homogeneous samples for structural studies. For structure determination, the paper evaluates X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, emphasizing solutions to challenges like crystallization bottlenecks and resonance overlap in NMR. Key innovations include selenium-derivatized nucleic acids for crystallographic phasing and novel NMR experiments for dynamic analysis. The integration of these methodologies enables precise structural insights critical for optimizing aptamer-based therapeutics and diagnostics.
Applications
- PAGE can be applied in preparative scenarios, including the small-scale purification of radioactive single-stranded probes and the large-scale purification of synthetic polynucleotides.
- HPLC offers exceptional purification capabilities for a wide range of compounds, including (5'-monomethoxytrityl 1, 5'-dimethoxytrityl 1,2, fluorescein, phosphorothioate 4, tert-butyldimethylsilyl 5,7, and N-acetyl 2-aminofluorene 3,10) protected and deprotected oligomers. These columns ensure excellent recovery rates, allowing for efficient isolation and purification of these compounds while maintaining their structural integrity.
Advantages
- The application of PAGE for the separation of polynucleotides larger than 50-60 m in length is well-established and highly efficient. This technique provides exceptional resolution and allows for precise separation of these extended nucleotide sequences. It is important to understand their structures and functions.
- HPLC is directly compatible with MS instruments and that is easy for the identification of individual peaks.
- This coupling provides for the efficient characterization and analysis of compounds within the sample. That provides valuable information on their molecular structures, composition, and fragmentation patterns.
Frequently Asked Questions
Associated Services
Our DNA and RNA purification delivers high-integrity nucleic acids essential for genomics and transcriptomics studies. To unlock deeper insights into glycan-mediated biological recognition, critical for understanding infection, immunity, and cellular communication, we provide advanced Glycan Microarray Assays. These platforms rapidly profile interactions between carbohydrates and diverse biomolecules (e.g., antibodies, lectins, viruses), enabling high-throughput functional glycomics:
- Synthetic Glycan Microarray Assay
- Sialylated Oligosaccharides Microarray Assay
- Glycosaminoglycan (GAG) Microarray Assay
- ABH Blood Type I-VI Antigen Microarray Assay
As a leading company in the field of glycobiology, CD BioGlyco excels in DNA and RNA purification. We possess several advantages that set us apart from others. We employ state-of-the-art purification techniques to ensure efficient and pure extraction of the target molecules. Besides, our research team possesses extensive knowledge and experience in the field. If you would like to know more about our services, we encourage you to contact us for further information.
References
- Lee, H.H.; et al. Terminator-free template-independent enzymatic DNA synthesis for digital information storage. Nature Communications. 2019, 10(1): 2383. (Open Access)
- Zhang, Q.; et al. Recent methods for purification and structure determination of oligonucleotides. International Journal of Molecular Sciences. 2016, 17(12): 2134. (Open Access)
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform




